Back to top
more

BioMarin Pharmaceutical (BMRN)

(Delayed Data from NSDQ)

$66.60 USD

66.60
1,644,379

+0.71 (1.08%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $66.63 +0.03 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

BioMarin's (BMRN) Hemophilia Gene Therapy Gets Nod in EU

by Zacks Equity Research

BioMarin's (BMRN) Roctavian is the first gene therapy to get approval for hemophilia A in the European Union. The therapy has also been granted a 10-year market exclusivity.

Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal

by Zacks Equity Research

Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline

Roche (RHHBY) Influenza Drug Gets FDA Nod for Children

by Zacks Equity Research

Roche (RHHBY) obtains FDA approval for expanded indication of influenza drug Xofluza.

CRISPR Therapeutics (CRSP) Q2 Earnings & Sales Miss Estimates

by Zacks Equity Research

CRISPR Therapeutics (CRSP) reports a wider-than-expected Q2 loss. Revenues also miss estimates.

Clearwater Paper and Logitech International have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Clearwater Paper and Logitech International are part of as Zacks Bull and Bear of the Day article.

John Blank headshot

Four Giant Tech Groups Keep the S&P 500 Aloft: Zacks August Market Strategy

by John Blank

The S&P 500 index -- and the broader underlying U.S. economy -- is now tied directly to the success of just four major converging, tech business groups.

BioMarin's (BMRN) Q2 Earnings Top, Voxzogo Drives Sales

by Zacks Equity Research

Biomarin Pharmaceutical's (BMRN) second-quarter earnings and sales beat estimates. BMRN slightly raises its sales guidance for the year.

BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

BioMarin (BMRN) delivered earnings and revenue surprises of 37.21% and 3.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Factors to Note Ahead of Humana (HUM) Q2 Earnings Release

by Zacks Equity Research

Humana's (HUM) second-quarter results are likely to reflect higher premiums from the Retail segment and overall membership growth, partly offset by elevated technology-linked investments.

Novo Nordisk's (NVO) Haemophilia A Study Meets Safety Endpoint

by Zacks Equity Research

Novo Nordisk's (NVO) phase I & II FRONTIER1 dose-escalation study investigating Mim8 for treating people with haemophilia A meets its primary safety endpoint.

BioMarin (BMRN) Gets CHMP Nod for Hemophilia Drug Roctavian

by Zacks Equity Research

BioMarin (BMRN) receives a positive CHMP opinion for Roctavian, its gene therapy for treating adults with hemophilia A. The European Commission's decision is expected by the third quarter of 2022.

BioMarin (BMRN) Stock Jumps 5.4%: Will It Continue to Soar?

by Zacks Equity Research

BioMarin (BMRN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

BioMarin (BMRN) Delays FDA Re-Submission for Hemophilia Drug

by Zacks Equity Research

BioMarin (BMRN) posts follow-up data from a phase I/II study on its gene-therapy candidate for hemophilia A. However, the stock falls 7% as management plans to defer the candidate's BLA filing.

BioMarin (BMRN) Down 4.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates

by Zacks Equity Research

Novo Nordisk (NVO) reports better-than-expected results for Q1. Sales are aided by growth in Diabetes and Obesity Care on higher GLP-1 revenues.

ResMed (RMD) Q3 Earnings Miss Estimates, Margins Decline

by Zacks Equity Research

Strong demand for sleep and respiratory care devices contributed to ResMed's (RMD) fiscal third-quarter sales performance.

Alnylam (ALNY) Misses on Q1 Earnings, Lowers '22 Revenue View

by Zacks Equity Research

Alnylam's (ALNY) earnings and sales fall shy of estimates in the first quarter of 2022. The company cuts 2022 guidance for net product revenues. Shares down.

BioMarin (BMRN) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Biomarin Pharmaceutical's (BMRN) first-quarter earnings and sales beat estimates. BMRN also raises its financial guidance for 2022 Voxzogo sales by $10 million.

Alkermes (ALKS) Q1 Earnings Beat Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Alkermes (ALKS) rides high on both earnings and sales beating estimates in the first quarter of 2022.

BioMarin Pharmaceutical (BMRN) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

BioMarin (BMRN) delivered earnings and revenue surprises of 44.74% and 2.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Kanishka Das headshot

Drug/Biotech Stocks' Apr 27 Q1 Earnings Roster: GSK, AMGN & More

by Kanishka Das

Let us take a look at four drug/biotech companies, namely, GSK, AMGN, ALKS and BMRN, which are due to release their quarterly results on Apr 27.

Why Is BioMarin (BMRN) Up 4.6% Since Last Earnings Report?

by Zacks Equity Research

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sanofi's (SNY) Hemophilia A Candidate Meets Study Endpoints

by Zacks Equity Research

Sanofi (SNY) and Sobi's factor VIII replacement therapy candidate, efanesoctocog alfa, achieves clinically meaningful prevention of bleeds in people with severe hemophilia A